RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives
Source : https://www.sciencedirect.com/science/article/abs/pii/S0163725823000086?via=ihub
Available online 9 January 2023, 108344 Author links open overlay panel Alfredo Addeo a f g Vivek Subbiah Person e Envelope Show more Precision oncology informed by genomic information has...
/>
Conclusions: RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series
Source : https://tlcr.amegroups.com/article/view/70603/html
IMMUNOTARGET represents an international collaborative effort to document the benefit of anti-programmed cell death 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) immune monotherapy among patients with advanced non-small cell lung...
Conclusions: Conclusions: Not all driver oncogene subtypes of NSCLC are equally responsive to immune monotherapy, however even among patients with well-validated gene rearranged NSCLC which has traditionally been considered immune hyporesponsive, objective responses can occur. Additional explorations of the features associated with and...
Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36628459/
In the era of precision medicine, with the deepening of the research on malignant tumor driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small-cell lung...
Conclusions: This article will review the latest research about the molecular characteristics, pathogenesis, detection, and clinical treatment strategies of RET rearrangements especially in China.
Quantifying the value of multi-gene testing in resected early-stage lung adenocarcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36494074/
CGP can identify driver alterations and accelerate the start of first-line therapy at recurrence. It may also represent a cost-effective approach for avoiding futile adjuvant ICI in patients with drivers...
Conclusions: CGP can identify driver alterations and accelerate the start of first-line therapy at recurrence. It may also represent a cost-effective approach for avoiding futile adjuvant ICI in patients with drivers that have historically lacked activity with ICI in metastatic disease.
Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations - Journal of Molecular Modeling
Source : https://link.springer.com/article/10.1007/s00894-022-05429-9
Objective RET (rearranged during transfection) kinase, as a transmembrane receptor tyrosine kinase, is a therapeutic target for several human cancer such as non-small cell lung cancer (NSCLC) and thyroid cancer....
Conclusions: The obtained results may provide understanding of the mechanism of pralsetinib resistance to the non-gatekeeper RET G810C mutant.